What question did this study set out to answer?

This research examines the long-term efficacy and safety of domperidone in treating patients with gastroparesis symptoms.

April 5, 2026

Efficacy and Safety of Domperidone for Patients With Symptoms of Gastroparesis; Long‐Term Results

Key Result

Domperidone provided safe long-term symptom relief for gastroparesis, with 36% of patients (298 of 827) continuing treatment for a mean of 7.6 years and reporting moderate improvement.

Key Points

This research examines the long-term efficacy and safety of domperidone in treating patients with gastroparesis symptoms.
Long-term treatment assessment of patients with gastroparesis using domperidone.
Observation of 827 patients, with a focus on those who continued treatment.
Mean treatment duration recorded at 7.6 years.
36% of patients (298 out of 827) continued domperidone treatment long-term.
Patients reported moderate improvement in symptoms over time.
Domperidone treatment was found to be safe with careful monitoring.

Structured PICO

Does long-term domperidone improve symptoms in patients with gastroparesis?

Population

Patients with symptoms of gastroparesis

Intervention

Long-term domperidone

Outcome

Treatment continuation and patient-reported symptom improvementpatient reported

Long-term domperidone treatment is effective and safe for symptom management in select patients with gastroparesis.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

In this study of patients treated with long term domperidone for symptoms of gastroparesis, 298 of 827 (36%) patients continued treatment for a mean of 7.6 years with patients reporting being moderately better. Thus, in select patients, domperidone treatment is an effective long-term treatment for symptoms of gastroparesis, able to be safely administered with careful patient monitoring.

Bookmark